small
valuabl
class
product
sinc
commerci
firm
initi
clinic
studi
involv
total
mab
date
one
product
palivizumab
approv
eight
candid
current
clinic
studi
commerci
mab
studi
antivir
agent
clinic
either
directli
indirectli
target
human
immunodefici
viru
respiratori
syncyti
viru
hepat
c
viru
infect
howev
abil
mab
bind
specif
target
util
variou
antiinfect
mode
action
would
seem
make
well
suit
prevent
andor
treatment
wider
varieti
viral
diseas
number
factor
includ
continu
need
innov
medicin
viral
infect
global
spread
viral
infect
increas
govern
fund
studi
pathogen
countermeasur
prompt
compani
reconsid
mab
antivir
agent
public
sector
research
use
mab
emerg
pathogen
sever
acut
respiratori
syndrom
coronaviru
may
alreadi
provid
candid
develop
antibodi
produc
immun
system
combat
inform
futur
effort
research
develop
innov
agent
overview
trend
commerci
invad
organ
virus
prior
develop
develop
mab
viral
infect
focu
mab
monoclon
antibodi
mab
polyclon
antibodi
prepar
hiv
rsv
hepat
c
viru
hcv
infect
provid
deriv
human
serum
use
prophylaxi
possibl
increas
effort
develop
mab
treatment
number
viral
infect
mab
emerg
pathogen
discuss
design
function
use
variou
mode
action
seem
well
suit
use
antivir
intervent
howev
mab
analysi
criteria
inconveni
administ
compar
oral
antibiot
provid
protect
infect
much
shorter
time
period
sinc
found
tuft
center
studi
compar
vaccin
mab
also
tend
expens
drug
develop
collect
data
develop
either
antibiot
vaccin
consequ
past
approv
therapeut
vaccin
data
mab
sponsor
mab
intervent
choic
infecti
clinic
preclin
studi
commerci
firm
collect
diseas
fact
mab
infecti
diseas
compris
survey
pharmaceut
biotechnolog
firm
total
number
mab
clinic
develop
inform
public
domain
eg
press
releas
one
product
palivizumab
prevent
respiratomed
literatur
commerci
mab
studi
clinic
ry
syncyti
viru
rsv
infect
highrisk
infant
current
candid
studi
primarili
abil
prevent
treat
market
due
recent
focu
emerg
viral
diseas
viral
infect
identifi
nonspecif
immunomodulatori
sever
acut
respiratori
syndrom
sar
limit
mab
exclud
mab
enter
clinic
studi
betreat
option
vaccin
exist
situat
might
tween
compos
either
singl
mab
chang
combin
mab
mab
cocktail
juli
develop
statu
mab
eight
also
design
pursu
quarri
interior
cell
clinic
studi
yet
approv
countri
five
though
complic
mode
action
compar
phase
one
phase
iii
one
phase
ii
one
phase
iii
mechan
develop
one
approv
us
countri
compani
sponsor
clinic
studi
develop
discontinu
mab
mab
either
monotherapi
mab
cocktail
consid
discontinu
clinic
studi
studi
identiprevent
treatment
infect
virus
virus
fie
ongo
recent
complet
sponsor
compawer
hiv
mab
rsv
mab
hcv
cytomegaloviru
ny
indic
addit
studi
plan
near
mab
hepat
b
viru
mab
human
rhinoviru
futur
preclin
categori
compris
candid
mab
candid
inlicens
well
selforiginatbeen
test
anim
total
nine
antivir
mab
spone
result
like
repres
promis
sore
least
part
commerci
firm
identifi
mab
commerci
potenti
indic
nearli
half
mab
either
origin
compani
licens
com
mab
human
quarter
human
mab
mercial
govern
academ
sourc
data
updat
remaind
either
murin
chimer
chang
note
juli
bispecif
antibodi
human
human
chimer
mab
either
four
product
candid
mab
cocktail
trend
toward
studi
antibodi
antivir
agent
mab
observ
candid
enter
clinic
studi
four
period
shown
figur
largest
number
antibodi
complex
glycoprotein
produc
blymphomab
began
studi
four
cyte
molecul
bind
help
elimin
foreign
mab
viral
infect
enter
clinic
studi
infecti
pathogen
bodi
antibodi
yshape
two
branch
attach
singl
stem
tip
branch
current
commerci
clinic
develop
bind
target
stem
also
call
crystalliz
fragment
fc
perform
sever
function
includ
activaof
mab
data
set
major
tion
compon
human
immun
system
specif
hiv
rsv
hcv
infect
fact
mab
candid
bind
target
antibodi
recruit
effector
cell
eg
clinic
studi
three
infect
see
tabl
neutrophil
macrophag
natur
killer
cell
activ
complemost
mab
current
studi
potenti
treatment
hiv
ment
destroy
target
two
mode
action
infect
though
none
progress
phase
ii
studref
antibodydepend
cell
cytotox
adcc
i
antivir
mab
phase
iii
antirsv
mab
complementdepend
cytotox
cdc
respect
motavizumab
improv
version
approv
antimedi
fc
portion
molecul
five
rsv
agent
palivizumab
two
mab
intend
treatment
class
antibodi
abund
igg
patient
hcv
infect
current
phase
import
four
isotyp
within
igg
class
human
igg
note
result
phase
ii
studi
gener
isotyp
vari
abil
induc
adcc
cdc
like
differenti
affin
immun
system
compon
four
isotyp
effect
induc
adcc
cdc
monoclon
version
antibodi
origin
produc
singl
blymphocyt
cell
genet
manipul
allow
gene
multipl
sourc
blymphocyt
eg
mous
human
combin
result
chimer
human
mab
addit
number
method
current
avail
product
fulli
human
mab
includ
use
transgen
anim
phage
display
mab
natur
well
suit
intercept
hostil
invad
prompt
respons
immun
system
howev
mab
also
simpli
block
entri
infecti
agent
host
cell
target
human
cellular
compon
mode
action
might
desir
virus
mutat
rapidli
thu
provid
stabl
target
mab
design
assess
safeti
targetdosag
regimen
fusion
complet
core
viral
rna
protein
provid
suffici
data
abl
draw
conclus
releas
cell
insid
core
disassembl
efficaci
comparison
studi
result
eg
reduct
viral
content
reform
complex
viral
rna
transcrib
load
agent
revers
transcriptas
dna
complex
travel
nucleu
cell
enter
nucleu
dna
encod
viral
protein
incorpor
host
genom
monoclon
antibodi
mab
hiv
infect
integras
enzym
point
viral
dna
either
lie
dormant
proteinproduct
machineri
gener
viral
hiv
infect
current
global
pandem
affect
million
protein
integr
dna
though
studi
suggest
peopl
genet
composit
viru
highli
variabl
hiv
protein
also
produc
nonintegr
viral
greatli
increas
difficulti
design
drug
dna
coordin
activ
viral
compon
effect
treat
hiv
infect
two
main
type
viru
cellular
compon
need
produc
new
viral
mani
genet
distinct
viral
subtyp
ment
rna
protein
compris
new
viral
particl
preval
varieti
subdivid
three
packag
procedur
involv
viral
group
n
preval
group
cellular
compon
viru
bud
cell
matur
subdivid
least
nine
subgroup
clade
new
infecti
agent
widespread
clade
b
c
viru
current
standard
care
patient
hiv
highli
compos
viral
envelop
glycoprotein
gp
core
activ
antiretrovir
therapi
haart
compris
drug
contain
viral
rna
enzym
necessari
replic
cocktail
two
nucleosid
revers
transcriptas
inhibitor
clear
understand
hiv
enter
cell
replic
either
nonnucleosid
revers
transcriptas
inhibitor
proteas
emerg
critic
design
intervent
hiv
inhibitor
although
therapi
suppress
viral
replic
rnabas
viru
replic
without
host
low
level
viru
elimin
consequ
lifelong
cellular
machineri
consequ
viru
must
bind
adher
drug
regimen
necessari
furthermor
viral
enter
host
cell
infect
initi
envelop
protein
spike
resist
drug
cocktail
occur
drug
occur
via
two
step
procedur
avail
haart
associ
toxic
eg
surfac
envelop
bind
receptor
coal
dysfunct
hepatotox
lipodystrophi
receptor
chemokin
cc
motif
receptor
transmembran
envelop
mediat
fusion
viral
limit
exist
treatment
alternaenvelop
cell
membran
tive
compon
current
avail
drug
cocktail
need
date
total
commerci
sponsor
mab
gest
factor
involv
host
activ
studi
treatment
hiv
infect
major
immun
system
implic
cell
loss
although
candid
target
hiv
envelop
protein
six
exact
mechan
phenomenon
well
undermab
target
two
target
two
mab
stood
one
theori
suggest
persist
declin
cocktail
target
howev
one
lymphocyt
due
partial
action
cytotox
mab
mab
kaketsuken
japan
lymphocyt
therefor
block
activ
lymphocyt
remain
clinic
studi
yet
efficaci
data
avail
functionassoci
molecul
cytotox
lymphocyt
might
help
reduc
deplet
directdu
issu
associ
directli
target
hiv
eg
high
ly
due
hiv
mab
administ
low
viral
mutat
rate
altern
method
block
progress
dose
mgkg
phase
iii
studi
although
definit
hiv
infect
use
mab
explor
three
mab
efficaci
data
yet
avail
sinc
mab
current
clinic
develop
target
cellular
receptor
use
affect
hiv
directli
must
use
conjunct
antivir
viru
gain
entri
lymphocyt
entri
drug
inhibitor
ei
class
hiv
drug
one
mab
tanox
houston
tx
usa
target
two
mab
progen
tarrytown
ny
usa
mab
respiratori
syncyti
viru
infect
human
genom
scienc
rockvil
md
usa
target
mab
undergon
preliminari
safeti
efficaci
rsv
common
human
pathogen
primarili
infect
phase
ii
studi
phase
ii
studi
respiratori
epitheli
cell
like
hiv
hcv
rsv
enadminist
infect
patient
intraven
dose
velop
rna
viru
viral
envelop
gpf
mediat
fusion
mgkg
mgkg
mab
well
toler
reduc
envelop
host
cell
membran
process
also
requir
viral
load
dose
although
reduct
greater
f
protein
infect
cell
subsequ
fuse
mgkg
dose
us
fda
request
addit
dosefind
ing
format
multinucl
mass
call
syncytia
studi
given
fast
track
design
f
protein
rsv
attract
target
therapeut
entitl
sponsor
compani
addit
input
fda
intervent
protein
sequenc
similar
across
viral
clinic
studi
period
date
two
mab
strain
rsv
caus
lower
respiratori
tract
infect
infant
subject
preliminari
safeti
studi
one
children
although
sever
rsv
diseas
usual
develop
mab
also
given
fast
track
design
infant
immunosuppress
individu
highrisk
group
inbi
fda
clude
infant
six
month
age
prematur
infant
ei
class
mab
alreadi
face
competit
drug
without
chronic
lung
diseas
infant
congenit
heart
similar
mode
action
one
ei
peptid
drug
enfuvirtid
diseas
immunodefici
trimerishoffmann
laroch
usa
alreadi
approv
date
total
four
commerci
sponsor
mab
small
molecul
ei
drug
maraviroc
pfizer
usa
latestag
studi
prophylaxi
treatment
rsv
infect
clinic
develop
enfuvirtid
amino
acid
synthet
pepfour
mab
target
rsv
f
protein
two
antirsv
mab
tide
approv
fda
bind
viral
disrupt
felvizumab
discontinu
one
motavizumab
fusion
viru
cell
membran
two
phase
iii
current
phase
iii
anoth
palivizumab
alreadi
marstudi
enfuvirtid
administ
twice
daili
kete
worldwid
interestingli
despit
target
mean
viral
load
reduc
palivizumab
felvizumab
demonstr
efficaci
phase
week
maraviroc
orallydeliv
small
molecul
iii
studi
subsequ
direct
comparison
vitro
bind
current
phase
iii
studi
drug
reduc
vivo
activ
agent
reveal
palivizumab
viral
load
least
dose
administ
notabl
potent
felvizumab
antigen
bind
viru
twice
daili
earlier
studi
fda
given
maraviroc
fast
neutral
fusion
inhibit
assay
also
display
track
design
enhanc
activ
cotton
rat
model
rsv
infect
altern
approach
treat
hiv
involv
palivizumab
medimmun
usa
approv
fda
target
viru
hiv
infect
character
indic
prevent
seriou
lower
respiracrimin
destruct
lymphocyt
critic
tori
tract
diseas
caus
rsv
pediatr
patient
high
risk
compon
human
immun
system
ad
rsv
diseas
palivizumab
target
epitop
antigen
complex
diseas
declin
lymphocyt
site
gpf
rsv
prevent
viral
bind
cell
mab
predict
present
rna
level
sugadminist
intramuscularli
dose
mgkg
monthli
basi
month
total
clinic
studi
involv
irsael
phase
ii
studi
discontinu
favor
patient
perform
palivizumab
mab
cocktail
compris
anoth
studi
adult
volunt
prophylaxi
studi
conhcv
mab
mab
cocktail
consid
separ
duct
pediatr
patient
treatment
studi
adult
distinct
product
test
singl
agent
pediatr
patient
phase
iii
impactrsv
studi
dose
phase
ii
studi
howev
preclinipalivizumab
reduc
risk
rsvassoci
hospit
cal
data
suggest
mab
cocktail
might
efficaci
placebo
vs
palivizumab
high
risk
infant
phase
studi
product
candid
initi
rsvassoci
hospit
reduc
given
fast
track
design
fda
children
prematur
without
bronchopulmonari
dyspla
third
mab
bavituximab
peregrin
pharmaceut
tussia
tin
ca
usa
phase
develop
treatment
hcv
motavizumab
next
gener
antirsv
mab
current
infect
although
mab
potenti
target
phase
iii
studi
deriv
palivizumab
also
target
virus
process
exit
host
cell
envelop
rsv
gpf
mab
potent
antirsv
neutral
activivirus
hcv
hiv
rsv
incorpor
compon
ty
palivizumab
greater
bind
affin
host
cell
membran
viral
envelop
bavituximab
increas
neutral
activ
time
target
phosphatidylserin
resid
insid
cellular
potent
cotton
rat
model
howev
detail
efficaci
membran
mab
thu
bind
extracellular
viru
motavizumab
human
limit
phase
iii
studi
assess
phosphatidylserinemodifi
envelop
protein
without
afth
reduct
hospit
due
rsv
highrisk
infant
fect
host
cell
bavituximab
administ
dose
complet
studi
motavizumab
compar
mgkg
phase
ia
studi
mab
show
evid
antiwith
palivizumab
children
full
result
hcv
activ
well
toler
interestingli
mab
may
studi
yet
releas
preliminari
result
indic
also
use
indic
sinc
phosphatidylserin
motavizumab
show
noninferior
primari
endpoint
also
expos
outsid
tumor
vasculatur
bavituxreduc
incid
hospit
caus
rsv
imab
also
clinic
studi
treatment
solid
tumor
motavizumab
vs
palivizumab
show
superior
commerci
preclin
develop
secondari
endpoint
reduc
incid
rsvspecif
medic
attend
outpati
lower
respiratori
infect
type
number
mab
might
enter
clinic
studi
motavizumab
vs
palivizumab
number
studi
sponsor
compani
assess
necessarili
ongo
accur
predict
base
commerci
preclin
pipelin
degre
unpredict
present
preclin
mab
mab
hepat
c
viru
infect
develop
academ
academ
institut
exclud
data
set
discoveri
institut
might
like
hiv
hcv
envelop
rna
viru
mutat
licens
commerci
futur
consequ
rapidli
compris
numer
genet
distinct
viral
subth
result
discuss
probabl
undercount
total
type
infect
hcv
caus
chronic
inflamm
possibl
number
candid
unknown
degre
nevertheliv
hepat
lead
reduc
liver
function
less
examin
commerci
preclin
mab
indic
need
liver
transplant
viral
genom
describ
new
target
interest
tabl
ii
furthermor
studi
viru
lifecycl
hamper
size
group
nine
mab
suggest
whole
system
suitabl
cultur
viru
laboratori
industri
dedic
resourc
candid
antivir
mab
develop
decad
later
hcv
genom
enprogram
major
preclin
mab
target
code
two
envelop
protein
nonstructur
proeither
sar
coronaviru
scv
west
nile
viru
remain
tein
requir
replic
eg
proteas
littl
known
four
product
target
rabi
two
mab
hepat
b
influenza
virion
structur
hcv
gain
entri
hepatocyt
one
mab
viru
interact
viral
envelop
protein
cell
surfac
receptor
discuss
date
total
three
commerci
sponsor
mab
studi
treatment
hcv
infect
two
mab
target
date
major
commerci
clinic
develop
envelop
protein
interfer
viral
entri
host
mab
viral
infect
focus
product
might
meet
cell
one
xtl
biopharmaceut
rehovot
exist
medic
need
new
therapi
provid
suffici
emerg
pathogen
crimeancongo
hemorrhag
fever
viru
rabi
scv
importantli
emphasi
develop
human
mab
along
human
product
compris
commerci
mab
clinic
studi
tie
public
privat
sector
notori
intric
fact
preclin
mab
scv
west
nile
viru
infect
attribut
commerci
sector
develop
least
input
public
sector
howev
remain
seen
whether
mab
infect
occur
high
level
sporad
would
like
provid
poor
return
invest
commerci
mab
could
potenti
critic
first
respons
measur
case
public
health
crisi
substanti
public
sector
input
might
requir
get
product
market
nih
current
emphasi
translat
medicin
might
eas
progress
less
commerci
attract
product
process
preclin
clinic
develop
despit
obstacl
develop
innov
mab
prophylaxi
treatment
viral
diseas
reason
return
invest
opportun
type
exist
numer
cautiou
optim
scientif
advanc
uncov
potenti
viral
diseas
current
treatment
option
new
viral
target
mab
mode
action
new
possibl
exist
optim
ii
effect
vaccin
avail
iii
market
design
safer
efficaci
mab
exampl
least
us
europ
defin
exampl
success
potenti
achiev
improv
design
found
agent
meet
criteria
mab
direct
hiv
case
mab
rsv
felvizumab
prove
rsv
hcv
infect
examin
commerci
efficaci
palivizumab
suffici
efficaci
appreclin
pipelin
suggest
similar
select
criteria
prove
motavizumab
show
improv
efficaci
compar
appli
major
candid
might
enter
clinic
palivizumab
even
potent
antirsv
mab
studi
near
futur
howev
case
mab
target
design
addit
increas
emphasi
public
scv
current
low
incid
new
infect
beg
quesand
privat
sector
studi
mab
viral
countermeasur
tion
whether
preclin
candid
progress
although
might
serv
immedi
purpos
provid
mab
use
defens
public
health
measur
product
infect
either
prevent
measur
treatment
might
also
avail
provid
inform
potenti
use
develop
vacth
current
dearth
commerci
research
develop
cine
either
case
result
could
greatli
benefit
public
health
mab
emerg
pathogen
might
amelior
somewhat
human
studi
would
ethic
feasibl
author
thank
matthew
dewitz
julia
wenger
assist
data
collect
colleagu
tuft
csdd
critic
review
factor
might
inde
bolster
somewhat
anem
manuscript
effort
industri
public
sector
appear
alreadi
author
conflict
interest
directli
relev
respond
challeng
vigor
way
numer
content
articl
mab
emerg
viral
diseas
earli
research
preclin
stage
academ
govern
institut
work
refer
focus
prioriti
pathogen
hanta
ebola
virus
sawyer
la
antibodi
prevent
treatment
viral
diseas
antivir
easili
dissemin
transmit
persontoperson
re
